Gynecomastia: pathophysiology, evaluation, and management.

Mayo Clin Proc

Division of Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Published: November 2009

Gynecomastia, defined as benign proliferation of male breast glandular tissue, is usually caused by increased estrogen activity, decreased testosterone activity, or the use of numerous medications. Although a fairly common presentation in the primary care setting and mostly of benign etiology, it can cause patients considerable anxiety. The initial step is to rule out pseudogynecomastia by careful history taking and physical examination. A stepwise approach that includes imaging and laboratory testing to exclude neoplasms and endocrinopathies may facilitate cost-effective diagnosis. If results of all studies are normal, idiopathic gynecomastia is diagnosed. The evidence in this area is mainly of observational nature and lower quality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770912PMC
http://dx.doi.org/10.1016/S0025-6196(11)60671-XDOI Listing

Publication Analysis

Top Keywords

gynecomastia pathophysiology
4
pathophysiology evaluation
4
evaluation management
4
management gynecomastia
4
gynecomastia defined
4
defined benign
4
benign proliferation
4
proliferation male
4
male breast
4
breast glandular
4

Similar Publications

Clinical Reasoning: A 32-Year-Old Man With Painless Bilateral Shoulder Girdle Weakness and Atrophy.

Neurology

November 2024

From the Departments of Neurology (N.B.G., J.K., D.K.), Neurosurgery (K.K.D.), and Radiology (Z.N.), Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

Article Synopsis
  • A 32-year-old man has experienced progressive weakness in his upper limbs for 14 months, along with gynecomastia and muscle wasting.
  • On examination, he showed weakness in key shoulder and arm muscles and sensory loss in certain nerve areas, with altered reflexes in his upper and lower limbs.
  • The report examines the clinical evaluation, possible diagnoses, tests needed, and treatment strategies for this specific condition of arm weakness.
View Article and Find Full Text PDF

Background: Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF). However, the difference in the clinical effects between eplerenone and spironolactone in individuals with HF remains uncertain. We aimed to assess the impact of eplerenone compared to spironolactone on clinical outcomes within the HF population.

View Article and Find Full Text PDF

Purpose: Andrological pathologies in the adulthood are often the results of conditions that originate during childhood and adolescence and sometimes even during gestation and neonatal period. Unfortunately, the reports in the literature concerning pediatric andrological diseases are scares and mainly concerning single issues. Furthermore, no shared position statement are so far available.

View Article and Find Full Text PDF

Male Reproductive Endocrine Disorders.

Prim Care

September 2024

Department of Family Medicine, Tidelands Health, 4320 Holmestown Road, Myrtle Beach, SC 29588, USA.

Article Synopsis
  • * Disorders within the hypothalamic-pituitary-gonadal axis can cause conditions like hypogonadism, gynecomastia, sexual dysfunction, and infertility, necessitating medical attention.
  • * Testosterone replacement therapy may be an option for men with symptomatic hypogonadism, but it carries potential risks, including azoospermia and effects on cardiovascular health, while sexual dysfunction often stems from psychological or metabolic issues.
View Article and Find Full Text PDF

New ways of mitigating aldosterone in cardiorenal disease.

Eur Heart J Cardiovasc Pharmacother

October 2024

Department of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Homburg University Hospital, Saarland University, Kirrberger Str. 100, Homburg 66424, Germany.

Article Synopsis
  • Steroidal mineralocorticoid receptor antagonists (MRAs) help manage conditions like heart failure and chronic kidney disease by blocking aldosterone, but they may have significant side effects and limited effectiveness in some types of heart failure.
  • New non-steroidal MRAs, like finerenone, show promise in improving outcomes for patients with diabetic nephropathy and heart failure, with guidelines recommending their use in type 2 diabetes and chronic kidney disease.
  • Other investigational drugs, such as baxdrostat and lorundostat, are being tested for their effectiveness in treating resistant hypertension without the adverse effects associated with steroidal MRAs.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!